Improving our understanding of viruses to help develop new medicines

Based on research at University College London, Arrow Therapeutics has developed an array of potential candidates for novel anti-viral drugs. Basic Research by Professor Ian Charles into molecular pathogenicity led to the creation of a novel technology termed Transposon-mediated Differential Hybridisation (TMDH), which allows researchers to analyse the genes of a target organism.

Arrow therapeutics was purchased by Astra Zeneca in 2007 for around $150m in cash, generating large financial returns for the researchers and the university. The products being developed by the company work to combat important pathogens such as Hepatitis C and Respiratory Syncytial Virus (RSV): they could therefore have enormous impacts on healthcare, and potentially save many lives.

Related case studies

People-powered research engaging the public and leading to real discoveries

Nearly 1.4 million citizen scientists from over 100 countries are collaborating online with researchers in fields ranging from astronomy to zoology, thanks to researchers at the University of Oxford.

Read more >

University of Cambridge - Delivering new treatments for multiple sclerosis

A multiple sclerosis treatment used by more than 24,000 people worldwide and judged the most cost-effective treatment for MS in 2014 was developed at the University of Cambridge.

Read more >